Viracta Therapeutics, Inc. Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021	FY2020 12 months to Dec 31, 2020	FY2019 12 months to Dec 31, 2019
Operating activities
Net loss
Net Income Loss
Adjustments to reconcile net loss to net cash used in by operating activities:
Gain on forgiveness of PPP Loan
Acquired in-process research and development
Share-based compensation expense
Accretion of investment discounts and depreciation
Amortization of debt discount and debt issuance costs
Gain on conversion of note receivable to equity investments
Depreciation and amortization
Amortization of premiums and accretion of discounts on short-term investments, net
Change in fair value of preferred stock warrant liability
Change in operating assets and liabilities:
Prepaid expenses and other current assets
Other assets
Accounts payable
Accrued clinical expense
Accrued compensation
Other accrued liabilities
Accrued expenses
Lease liabilities, net

Net cash used in operating activities

Investing activities
Purchases of marketable securities
Sale and maturities of marketable securities
Purchases of property and equipment
Purchased in-process research and development
Purchases of short-term investments
Proceeds from maturity of short-term investments
Cash acquired in connection with the Merger
Net cash provided by (used in) investing activities

Financing activities
Proceeds from notes payable, net of issuance cost
Principal payments on notes payable
Proceeds from debt, net of issuance costs
Issuance of common stock, net of issuance costs
Proceeds from issuance of common stock through controlled equity offering facilities, net
Proceeds from exercise of stock options and stock purchase rights
Issuance of preferred stock for cash, net of offering costs
Issuance of common stock upon option exercises and from employee stock plan
Net cash provided by financing activities

Net increase in cash and cash equivalents
Cash, cash equivalents and restricted cash at beginning of period
Cash, cash equivalents and restricted cash at end of period
Net decrease in cash and cash equivalents
Cash and cash equivalents at beginning of period
Cash and cash equivalents at end of period
Supplemental disclosure of cash flow information
Interest paid
Interest earned
Interest received
Operating lease right-of-use assets obtained in exchange for operating lease liabilities
Noncash financing activities
Warrants issued in connection with debt
Warrant liability reclassification to equity
Issuance of convertible preferred stock upon merger
Conversion of convertible preferred stock into common stock upon Merger
Conversion of notes receivable to equity investments
Issuance of common stock upon Merger

Comments